Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Sirens sound in occupied West Bank following Israeli detection of missile launch from Yemen.
Israeli media: Missile launch detected from Yemen.
Al Mayadeen's correspondent in Iran: Israeli aggression on city of Qom, south of Tehran.
Al Mayadeen's correspondent: 18 martyrs, 35 wounded in Israeli aggression on Iran's Eastern Azerbaijan Province.
Ritter: These operations do not happen overnight, as "Israel" needs to transfer capabilities to an area near Iran, such as Iraq.
Ritter: The Israeli strike on Iran is also an American message to China and Russia.
Former US Marine officer Scott Ritter: The US and "Israel" have decided that negotiations with Iran are merely a tactic to buy time ahead of a surprise attack.
Iranian media: Explosions heard in Tabriz.
Araghchi: Israeli aggression targeted nuclear facilities and residential areas, in violation of international law.
Iranian FM in phone call with Italian counterpart: Iran will deliver definitive response to Israeli aggression.

Politico: How Big Pharma exploits markets and keeps drug prices high

  • By Al Mayadeen English
  • Source: Politico
  • 12 Apr 2023 15:20
6 Min Read

Politico explains how Big Pharma is doing everything it can to keep competitors off the market for as long as possible.

  • x
  • How Big Pharma exploits markets and keeps drug prices high
    A pharmacy employee at a pharmacy in New York on December 23, 2009. (Reuters)

Several Big Pharma companies use a mix of tactics including patents, market exclusivity, and data protection to keep generic competitors out of the market.

The Big Pharma system is controlled by a complicated set of laws that shield new branded pharmaceuticals from unbranded competitors for a short time in order to keep cheaper generic competitors at bay.

The term used to describe the practice of gaming the pharmaceutical system employed by such companies is called evergreening. It has the potential to add billions of euros to the financial sheets of pharmaceutical firms, while costing EU nations substantially in lost savings.

Big Pharma firmly denies any misconduct, but the European Commission underlined the need for better enforcement of competition regulations in a 2009 study to avoid evergreening. Little has changed since then.

Now, a leaked draft of the EU's revised pharmaceutical law suggests that the Commission is preparing to crack down on evergreening.

Politico has taken a look at the most prevalent ways to scam the system — and how Big Pharma's European lobby organization EFPIA responds.

On Patents

Some believe that one medicine equals one patent. However, in the United States, AbbVie, for example, applied for almost 250 patents for its arthritis medicine Humira. While a drug's basic patent protects its chemical makeup, there are a variety of conceivable add-ons that firms might use to delay imitation medications. They include production techniques, distribution systems, and medication doses.

According to EFPIA, the European Patent Office maintains strict requirements and does not grant patents on the spur of the moment. Nevertheless, proprietary procedures do not preclude generic companies from producing the medicine; they simply have to find other means to do so.

On courtroom tricks

Related News

DOGE guns Politico: Is the Trump admin going after the media industry?

AIPAC heavily influences US lawmakers' 'Israel' perspectives: Politico

Patents for add-ons can be contested in court. Yet when it appears that a challenge may be successful, some pharmaceutical corporations will further complicate matters by filing new patent applications with the European Patent Office. Each of these divisional patents is tied to a secondary patent, such as a manufacturing technique, and provides the same length of protection.

Even if a generics business successfully challenges the secondary patent — or, more often than not, the original company withdraws the patent before the challenge is won — generic firms must also fight the associated divisional patent. This process might take up to seven years.

Adrian van den Hoven, head of Medicines for Europe, the generics lobby group, says this strategy is often used to delay generic and biosimilar competition.

EFPIA states that the issue has been "blown hugely out of proportion," with divisionals accounting for around 10% of all new European patent applications. Divisional patents have the same expiration date as the connected parent patent and cannot make the same claims.

On rare disease groups

Medicines for uncommon disorders are given particular consideration, with a decade of market exclusivity. This means that if the European Medicines Agency approves a new drug for a condition that affects no more than five in 10,000 people in the EU, and for which no effective treatments are available — or if it adds significant benefit to existing treatments — copycat medicines must wait ten years to enter the market.

There are worries about Big Pharma's interest in subdividing common diseases and intentionally establishing uncommon disease groupings, or, "salami-slicing" in order to benefit from these incentives.

According to EFPIA, it is correct that illnesses are classified by kind as well as genetic variations, as this is scientific truth. In any scenario, when other therapies are available, incentives will only be provided for goods that clearly benefit patients.

On patent linkage

The so-called Bolar exemption is intended to limit patent authority. It enables unbranded pharmaceutical businesses to begin developing knockoff medications before patents on genuine drugs expire, allowing them to be ready to join the market when the time comes.

Yet, various EU nations have varying conceptions of how broadly the exemption should be used. In certain cases, generics companies can begin negotiating pricing with health authorities for cheaper alternatives even before they are formally launched. In others, however, including Germany, Italy, and Poland, patents can prevent reimbursement authorities from even speaking with generics businesses, a process known as patent linkage.

The EFPIA refutes that the Bolar exemption does not apply to price and reimbursement applications. Several generics companies are already releasing drugs in Central and Eastern European nations where intellectual property protections are in place, and broadening the Bolar exemption would encourage more of the same.

On enforced licensing

Compulsory licensing, in which governments can override patents and enable other businesses to manufacture a medication in an emergency, has long been viewed as an existential danger by the industry. Big Pharma has campaigned hard against implementation and has found a valuable friend in EU legislation - regulatory data protection. While mandatory licensing may compel pharma to divulge a medicine's formula, it is not required to provide data from drug trials, which a competing business requires to have its version authorized.

The industry has been vocal in its opposition to expanding the use of forced licensing. For example, in a 2019 submission to the United States government's yearly blacklist of nations that do not abide by its intellectual property norms, the pharmaceutical industry successfully fought to include countries that employ forced licensing in a way that they did not approve of.

The EU's pharmaceutical law may modify this, enabling data and market protection to be suspended in times of public health emergency.

The EFPIA says that firms that create a medicine should be permitted to bring it to market since they are the most knowledgeable about the technology. For good reason, compulsory licensing is a last-resort option, and "undue willingness" to use the policy weakens investor trust and hurts innovation.

  • Politico
  • pharmaceutical company
  • pharmaceuticals
  • Big Pharma

Most Read

The logo of the Iranian Ministry of Intelligence (wikidata)

Iran acquired thousands of sensitive Israeli documents: Exclusive

  • Politics
  • 7 Jun 2025
'Israel' launches major strike against Iran's nuclear program

'Israel' launches massive aggression on Iran

  • MENA
  • Today
Iranian demonstrators walk on a caricature of the Israeli Prime Minister Benjamin Netanyahu during the annual Quds Day rally in support of Palestinians, in Tehran, Iran, Friday, March 28, 2025 (AP)

Iran hits 'Israel' hard without arms; intel breach lays Tel Aviv bare

  • Politics
  • 7 Jun 2025
The flag of the International Atomic Energy Agency flies in front of its headquarters during an IAEA Board of Governors meeting in Vienna, Austria, Wednesday, Nov. 22, 2023. (AP)

Tehran unravels documents exposing secret IAEA-'Israel' collusion

  • Politics
  • 12 Jun 2025

Coverage

All
War on Gaza

Read Next

All
Global condemnations mount against Israeli aggression on Iran
Politics

Global condemnations pour in against Israeli aggression on Iran

President Donald Trump attends the UFC 316 mixed martial arts event Saturday, June 7, 2025, in Newark, New Jersey (AP)
MENA

US denies role in attacks on Iran, yet vows to defend 'Israel'

Vehicles drive past an anti-Israeli banner showing missiles being launched, in a square in downtown Tehran, Iran, Friday, April 19, 2024. (AP)
Politics

Political, military Iranian figures vow revenge, slam US complicity

AEOI condemns IAEA silence after Israeli aggression on nuclear site
Politics

AEOI slams IAEA's silence despite Israeli aggression on nuclear site

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS